Ascendis Pharma A/S, a global biopharmaceutical company, focuses on applying its innovative TransCon technology platform to make a meaningful difference for patients.
Guided by the company’s core values of Patients, Science, and Passion, and followi…
Analysis
Middle-of-the-road
Ascendis Pharma A/S sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is fair. The owner-earnings multiple stands at 23.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 9% a year, against analyst forecasts of 93%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is fragile. The company scores 18/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202650
25
2026
All-time high
50
Mar 2026
All-time low
25
Jun 2026
Average rank
38
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
55
—
—
—
Price/Earnings
15
—
—
—
Price/Book
7
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
4
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.